David Veitch
Chief Executive Officer chez BASILEA PHARMACEUTICA AG
Fortune : 54 341 $ au 31/03/2024
Profil
David Veitch is currently the Chief Executive Officer at Basilea Pharmaceutica AG since 2018.
Prior to this, he was the President-European Operations at Savient Pharmaceuticals, Inc. from 2012 to 2013.
He also served as the SVP-European Marketing & Brand Commercialization at Bristol-Myers Squibb Pharmaceuticals Ltd.
from 2007 to 2011.
Mr. Veitch completed his undergraduate degree at the University of Bristol.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
BASILEA PHARMACEUTICA AG
0,01% | 31/12/2022 | 1 300 ( 0,01% ) | 54 341 $ | 31/03/2024 |
Postes actifs de David Veitch
| Sociétés | Poste | Début |
|---|---|---|
| BASILEA PHARMACEUTICA AG | Chief Executive Officer | 19/04/2018 |
Anciens postes connus de David Veitch
| Sociétés | Poste | Fin |
|---|---|---|
| SAVIENT PHARMACEUTICALS INC | Corporate Officer/Principal | 01/01/2013 |
Bristol-Myers Squibb Pharmaceuticals Ltd.
 Bristol-Myers Squibb Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Bristol-Myers Squibb Pharmaceuticals Ltd. manufactures pharmaceutical products. Its products are used for treatment of diseases like cancer, diabetes, arthritis, hepatitis, and psychiatric disorders. The company distributes products throughout the United Kingdom. Bristol-Myers Squibb Pharmaceuticals was founded in 1989 and is located in Uxbridge, UK. | Corporate Officer/Principal | 01/01/2011 |
Formation de David Veitch
| University of Bristol | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| BASILEA PHARMACEUTICA AG | Health Technology |
| Entreprise privées | 2 |
|---|---|
Savient Pharmaceuticals, Inc.
 Savient Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Savient Pharmaceuticals, Inc. operates as a specialty biopharmaceutical company, which develops, manufactures and markets pharmaceutical products. The company focuses on developing and commercializing KRYSTEXXA for the treatment of chronic gout in adult patients who do not respond to conventional therapy. It also sells and distributes branded and generic versions of oxandrolone, a drug used to promote weight gain following involuntary weight loss. The company was founded in 1980 is headquartered in East Brunswick, NJ. | Health Technology |
Bristol-Myers Squibb Pharmaceuticals Ltd.
Bristol-Myers Squibb Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Bristol-Myers Squibb Pharmaceuticals Ltd. manufactures pharmaceutical products. Its products are used for treatment of diseases like cancer, diabetes, arthritis, hepatitis, and psychiatric disorders. The company distributes products throughout the United Kingdom. Bristol-Myers Squibb Pharmaceuticals was founded in 1989 and is located in Uxbridge, UK. | Health Technology |
